✦ LIBER ✦

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

✍ Scribed by Pier Paolo Piccaluga; Michele Malagola; Michela Rondoni; Marilina Amabile; Stefania Paolini; Simona Soverini; Stavroula Gaitani; Giuseppe Visani; Michele Baccarani; Giovanni Martinelli

Book ID: 114792617
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 72 KB
Volume: 72
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2004.00212.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Increasing the BCR-ABL expression levels

Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia

✍ S. Grammatico; L. Elia; A.L. Peluso; L. Pedace; M. Matarazzo; A. Vitale; A. Rago 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 275 KB

A phase II trial of high-dose imatinib m

A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial

✍ Patrice Chevallier; Mathilde Hunault-Berger; Fabrice Larosa; Charles Dauriac; Ri 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 101 KB

High-dose imatinib mesylate combined wit

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

✍ Rea, D; Legros, L; Raffoux, E; Thomas, X; Turlure, P; Maury, S; Dupriez, B; Pign 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB